Unifaun and Consignor become nShift, Global Leader in Cloud Delivery Management Solutions
27.8.2021 13:08:00 EEST | Business Wire | Press release
nShift (www.nshift.com), global provider of cloud delivery management solutions for e-commerce shops, retailers, manufacturers and 3PL companies, announces its launch.
With over 100+ pre-built third-party integrations into e-commerce and other shippers’ most critical IT systems and an unmatched carrier library delivering connectivity into over 700+ carriers, nShift offers customers an end-to-end cloud platform to automate and optimize the entire delivery management process – from label creation to delivery tracking and last mile logistics to returns management. nShift’s solutions have successfully enabled almost 1 billion annual shipments globally for e-commerce shops, retailers, manufacturers and 3PL companies. Through its extensive carrier library, nShift has unparalleled shipping visibility and reach, unlocking significant scalability for its customers – from 1 to millions of shipments annually – across the globe.
“I am extremely honored and excited to be joining nShift at such a pivotal time in its growth,” said Lars Pedersen, who was recently appointed CEO of nShift. “While our name is changing, we are more committed than ever to continuing to provide the vital connectivity in delivery management, visibility, and efficiency for which our 90,000+ customers rely on us. We are thrilled to announce our new brand together with our latest e-commerce innovations, nShift Checkout and nShift Return (formerly known as Returnado). Our platform enables customers to worry less and ship smarter with up to 10-20% higher e-commerce-shop conversions, 60% fewer delivery related support calls, and 30% increase in repurchase rates on returned products.”
Through the acquisition of Returnado, a Stockholm-based e-commerce returns management provider, nShift adds critical technology to its cloud delivery management platform with a streamlined return process for shippers, carriers, and recipients. Returnado’s returns expertise spans marquee brands such as Helly Hansen and Asket and demonstrates its significant capabilities to serve a very complicated portion of the logistics value chain.
Marlin Equity Partners and Francisco Partners, two of the world's leading technology investors, will remain the majority stakeholders in nShift.
Peter Chung, a Managing Director at Marlin Equity Partners, said, “We are excited to continue delivering against the nShift mission of enabling our customers to worry less and ship smarter via the Company’s collective scale and breadth of its consolidated, end-to-end cloud delivery management platform. Today, e-commerce and other shippers have a singular platform from which they can eliminate geographical barriers to growth and drive supply chain efficiency and visibility all while improving the overall delivery experience for constituents across the logistics value chain.”
Petri Oksanen, a Partner at Francisco Partners, added, “This is an exciting step forward and the beginning of the next chapter of transformational growth for nShift. With the recent acquisition and integration of Returnado, we are in a position now more than ever to continue to deliver the very best solutions for our customers and help them solve first-to-last mile logistics challenges, deliver tangible cost savings, and drive innovation in our industry.”
About nShift (www.nshift.com)
Established in 2021, nShift is the global leading provider of cloud delivery management solutions enabling the frictionless shipment and return of almost 1 billion shipments across 190 countries. nShift’s software is used globally by e-commerce, retail, manufacturing and 3PL shippers. The company is headquartered in London and Oslo. It has over 450 employees across offices in Sweden, Finland, Norway, Denmark, United Kingdom, Poland, the Netherlands, Belgium, Romania and Switzerland.
Stakeholders
About Marlin Equity Partners (www.marlinequity.com)
Marlin Equity Partners is a global investment firm with over $7 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs. Marlin invests in businesses across multiple industries where its capital base, industry relationships and extensive network of operational resources significantly strengthen a company’s outlook and enhance value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 170 acquisitions. The firm is headquartered in Los Angeles, California with an additional office in London.
About Francisco Partners (www.franciscopartners.com)
Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch over 20 years ago, Francisco Partners has invested in more than 300 technology companies, making it one of the most active and longstanding investors in the technology industry. With more than $25 billion in assets under management, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential.
Companies Which Have Merged to Form nShift (note - all now rebranded as part of nShift with immediate effect)
About Returnado
Returnado is a Swedish e-commerce returns management platform launched in 2016. Returnado’s solutions optimize the “reverse e-commerce” returns process for retailers and consumers, and provides real-time analytics enabling customers to achieve 30%+ repurchase rates.
About Unifaun
Unifaun provides innovative delivery management solutions to carriers, shippers, and parcel recipients across the European transportation ecosystem. With an extensive partner ecosystem and carrier library, Unifaun enables customers to efficiently deliver almost 300 million shipments annually. Unifaun has over 200 employees across Sweden, Finland, Norway, Denmark, the Netherlands, Belgium, Germany, and Poland.
About Consignor
Consignor supports customers across the delivery processes by making it simpler, quicker, and cost-effective to ship orders to customers and by making delivery a competitive advantage. Consignor provides delivery management solutions, enabled through a wide-ranging carrier library, connecting shippers’ websites and warehouses with their customers. Consignor has more than 170 employees across offices in Oslo, Stockholm, Helsinki, Copenhagen, Aarhus, Bucharest, and London.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210827005148/en/
Contact information
For international media enquiries please contact:
Benjamin Webb // Amie Smith // Matthew Lloyd
benjamin@deliberate-pr.com // amie@deliberate-pr.com // matthew@deliberate-pr.com
+44 (0) 7930 408 224 // +44 (0) 7718 289 855 // +44 (0) 7533 116 062
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
